We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo

Expanded access is currently available for this treatment.
Verified July 2012 by Thomas R. Porter, MD, University of Nebraska
Sponsor:
ClinicalTrials.gov Identifier:
NCT00575549
First Posted: December 18, 2007
Last Update Posted: July 23, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Thomas R. Porter, MD, University of Nebraska
December 14, 2007
December 18, 2007
July 23, 2012
 
Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo
The purpose of this study is to prospectively analyze and compare conventional stress echocardiograms and real-time myocardial contrast stress echocardiograms; and to determine the effect of contrast agents used during real-time myocardial contrast stress echocardiograms on serum troponin I levels.
To compare two different stress echocardiograms (conventional Stress echocardiograms or Real-time Myocardial Contrast Stress Echocardiograms) that are in routine clinical use. The information, including the digital images that are collected during the stress tests is used to determine if the usse of specialized imaging techniques and ultrasound contrast can better detect blockage in blood flow to the heart and predict how patients outcome may be affected by this detection of a blockage.
Expanded Access
Other: Dobutamine: Perflutren Lipid Microsphere
Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
Other Name: Definity
Not Provided
 
Available
Contact: Thomas R Porter, MD 402-559-7977 trporter@unmc.edu
Contact: Stacey Therrien, BS 402-559-7977 stherrien@unmc.edu
United States
 
 
NCT00575549
Thomas R. Porter, MD, University of Nebraska
University of Nebraska
Bristol-Myers Squibb
Principal Investigator: Thomas R Porter, MD UNMC
University of Nebraska
July 2012